News

New World Medical relied on feedback from surgeons in the development of the device, which was registered with the FDA in October.

LumiThera has announced positive interim data in visual and ERG clinical outcomes in the ELECTROLIGHT pilot study in dry AMD patients.

To mark the 20th anniversary of its TECNIS IOLs, Johnson & Johnson Vision is launching the “See More” campaign to educate patients and physicians on what is possible with cataract surgery.

The session duration is 4 hours per week over the course of about 6 months, according to Jorge L. Alió, MD, PhD, FEBO, director of the course.

Rapid test allows healthcare professionals to make fast decisions at the point of care.

Investigators are studying the use of photobiomodulation in the treatment of dry age-related macular degeneration.

Following a successful Phase 2 study, a Phase 2/3 clinical trial for the compound is currently planned for mid-2021.

Investigators from the University of Pittsburgh and West Virginia University will collaborate on an international glaucoma laser study funded with a combined $15.2 million grant.

Paul S. Bernstein, MD, PhD, leads a team of University of Utah investigators that has developed a method for synthesizing large enough quantities of very-long-chain polyunsaturated fatty acids to evaluate their potential sight-preserving properties.

Fellows, residents from around the world show promise for future of retinal research.

The study focused the safety and tolerability of increasing doses of polihexanide eye drops in order to choose a dose that would be tested in a phase III clinical trial in patients with acanthamoeba keratitis.

Investigators at the Wilmer Eye Institute at the Johns Hopkins University School of Medicine conducting experiments in mouse tissues and human cells found that they may be able improve the success rate for regrowing nerve cells damaged by blinding diseases.

The Phase 1 clinical trial of EyePoint Pharmaceuticals Inc.’s EYP-1901 is underway. It is a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration.

Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.

The FDA has granted Fast Track designation to MeiraGTx's AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM).

Ocular symptoms in COVID-19 patients may be more common than previously thought — with sore eyes a significant sign of disease.

In observance of International Holocaust Remembrance Day this January 27, John H. Merey, MD, may be the only Holocaust survivor still in the practice of ophthalmology.

The investigational therapy met all primary endpoints of absence of inflammation at both Day 8 and Day 15 for the treatment of pain and inflammation following cataract surgery.

Neurophth Therapeutics, Inc (Neurophth) and AAVnerGene Inc have announced the launch of a strategic partnership that will grant Neurophth global rights to mutually select adeno-associated virus (AAV) capsids for the creation of the next-generation ophthalmic gene therapy.

Bausch + Lomb has enrolled 599 participants in the first of two Phase 3 studies evaluating perfluorohexyloctane as a first-in-class investigational drug to treat the signs and symptoms of dry eye disease associated with meibomian gland dysfunction.

A device developed by an Israeli startup was implanted in the eye of a patient, enabling him to recognize his family and read words.

See what ranked most popular in our top 10 stories of 2020.

Amid ramped up production of vaccines, CARES Act gives FDA power to head off potential drug shortfalls. Prevent Blindness is urging the FDA to use its authority to ensure TED treatment drug supply isn’t interrupted.

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

Amydis announced the successful completion of a pre-investigational new drug (IND) meeting with the FDA for its candidate AMDX-2011P, a small-molecule retinal tracer that targets amyloid beta to diagnosis amyloid angiopathy.

Two teams of researchers from Gyroscope Therapeutics and the University of Pennsylvania are joining forces to explore gene therapy targets for three specific serious eye diseases.

Tamara R. Fountain, MD, will serve as president of the American Academy of Ophthalmology after being elected by the organization’s community of ophthalmologists during its recent virtual annual meeting.

Topline data following completion of ALTISSIMO trial treatment phase expected in second quarter of 2021.